60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study 60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind 60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind 60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.

Study Demonstrates Superiority of VeraForm® Marker Over Clips for Tumor Bed Delineation Accuracy SAN FRANCISCO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an...

Metabolon to Develop accuGFR™ Kidney Function Test With Johns Hopkins and Tufts Medical Center More accurate kidney function test needed for chronic kidney disease“Silent killer” can go undetected without symptoms until patient has lost 90 percent of kidney function RESEARCH TRIANGLE PARK,...